162. 類天疱瘡（後天性表皮水疱症を含む。） Disease details / Clinical trials / Drug dev / DR info

2-[[[(2R)-1-[1-[(4-chloro-3-methylphenyl)methyl]-4- piperidinyl]-5-OXO-2-pyrrolidinyl]carbonyl]amino]- N,N,6-trimethyl-4-pyridinecarboxamide,dihydrochloride
   Alkahest, Inc.
      2020   Phase 2   EUCTR2019-001059-37-BG   Bulgaria;Germany
      2019   Phase 2   EUCTR2019-001059-37-DE   Bulgaria;Germany
A single blood sample FOR HLA typing
   Sechenov University
      2017   -   NCT05284929   Russian Federation
AC-203 1% topical ointment
   TWi Biotechnology, Inc.
      2017   Phase 2   NCT03286582   Taiwan
Adalimumab injection
   Massachusetts Eye and Ear Infirmary
      2025   Phase 1   NCT06926478   United States
AKST4290
   Alkahest, Inc.
      2020   Phase 2   NCT04499235   Germany
      2020   Phase 2   EUCTR2019-001059-37-BG   Bulgaria;Germany
      2019   Phase 2   EUCTR2019-001059-37-DE   Bulgaria;Germany
Allogeneic adipose tissue-derived mesenchymal stem cells expanded
   FUNDACION JIMENEZ DIAZ HEALTH RESEARCH INSTITUTE
      2022   Phase 2   EUCTR2021-005486-40-ES   Spain
Allogenic mesenchymal stem cell isolated from adipose tissue
   FUNDACION JIMENEZ DIAZ HEALTH RESEARCH INSTITUTE
      2022   Phase 2   EUCTR2021-005486-40-ES   Spain
Apremilast
   Universitair Medisch Centrum Groningen
      2019   Phase 2   EUCTR2018-002564-10-NL   Netherlands
Arava
   CHU de Limoges
      2007   -   EUCTR2007-003545-32-FR   France
Avdoralimab
   CHU NICE
      2020   Phase 2   EUCTR2020-002912-34-FR   France
   Centre Hospitalier Universitaire de Nice
      2020   Phase 2   NCT04563923   France
Azathioprine
   Washington University School of Medicine
      2022   Phase 2   NCT05263505   United States
Azathioprine or mycophenolate mofetil
   University Hospital Muenster
      1997   Phase 2   NCT00431119   Germany
Baricitinib
   Washington University School of Medicine
      2022   Phase 2   NCT05263505   United States
Benralizumab
   ASTRAZENECA AB
      2021   Phase 3   EUCTR2020-000287-32-IT   Australia;Bulgaria;France;Germany;Israel;Italy;Japan;Spain;United States
   AstraZeneca
      2021   Phase 3   NCT04612790   Australia;Bulgaria;China;France;Germany;Greece;Israel;Italy;Japan;Spain;United States
   AstraZeneca AB
      2021   Phase 3   EUCTR2020-000287-32-GR   Australia;Bulgaria;China;France;Germany;Greece;Israel;Italy;Japan;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000287-32-FR   Australia;Bulgaria;France;Germany;Greece;Israel;Italy;Japan;Spain;United States
      2021   Phase 3   EUCTR2020-000287-32-DE   Australia;Bulgaria;China;France;Germany;Greece;Israel;Italy;Japan;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000287-32-BG   Australia;Bulgaria;China;France;Germany;Greece;Israel;Italy;Japan;Spain;United Kingdom;United States
   Hibi Kazushige
      2021   Phase 3   JPRN-jRCT2071210014   Australia;Bulgaria;France;Germany;Israel;Italy;Japan;Spain;United States
Bertilimumab
   Immune Pharmaceuticals
      2016   Phase 2   NCT02226146   Israel;United States
BIV009
   Bioverativ, a Sanofi company
      2015   Phase 1   NCT02502903   Austria
Blood sample and cotton skin swabs
   CHU de Reims
      2015   -   NCT02874079   France
Blood sampling
   CHU de Reims
      2022   -   NCT06479018   France
Bone densitometry
   Centre Hospitalier Universitaire, Amiens
      2019   Phase 4   NCT03926377   France
Carboxymethylcellulose
   Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.
      2015   -   NCT02365675   Mexico
CC-10004
   Universitair Medisch Centrum Groningen
      2019   Phase 2   EUCTR2018-002564-10-NL   Netherlands
Cellcept® IN autoimmune bullous dermatoses
   University Hospital, Limoges
      2016   Phase 3   NCT02993133   France
Cellulose acetate with petrolatum
   Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.
      2015   -   NCT02365675   Mexico
Clobetasol 0.05% topical ointment
   TWi Biotechnology, Inc.
      2017   Phase 2   NCT03286582   Taiwan
Clobetasol decreasing measurement
   University Hospital, Bordeaux
      2024   -   NCT06148090   France
Clobetasol propionate
   Centre Hospitalier Universitaire, Amiens
      2019   Phase 4   NCT03926377   France
Clobetasol propionate + methotrexate
   University Hospital, Montpellier
      2008   Phase 3   NCT02313870   France
Clobetasol propionate alone
   University Hospital, Montpellier
      2008   Phase 3   NCT02313870   France
Clobetasol propionate cream treatment
   University Hospital, Rouen
      2015   Phase 4   NCT02360202   France
Clobetasolo propionato
   Dipartimento di Scienze della Salute dell'Università degli Studi di Firenze
      2023   Phase 2   EUCTR2021-001826-23-IT   Italy
Collagenase
   National Taiwan University Hospital
      2012   Phase 1   NCT02202642   Taiwan
Cortancyl 20 MG
   CHU-Hôpitaux de Rouen
      2018   Phase 3   EUCTR2018-001417-32-FR   France
      2009   -   EUCTR2008-005266-31-FR   France
Cotton gauze with petrolatum
   Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.
      2015   -   NCT02365675   Mexico
Cultivated oral mucosal epithelial sheet transplantation
   Seoul National University Hospital
      2014   Phase 1/Phase 2   NCT02149732   Korea, Republic of
Cutaneous biopsy
   CHU de Reims
      2022   -   NCT06479018   France
Cyclophosphamide
   CHU-Hôpitaux de Rouen
      2017   Phase 3   EUCTR2016-004666-26-FR   France
Cyclophosphamide 50MG oral tablet
   University Hospital, Rouen
      2019   Phase 3   NCT03295383   France
Cyclosporine
   The First Affiliated Hospital of Kunming Medical University
      2020   Phase 4   ChiCTR2000029007   China
   UNIVERSITA' CAMPUS BIOMEDICO
      2008   -   EUCTR2008-000480-41-IT   Italy
Dacortin
   ARGENX BV
      2023   Phase 3   EUCTR2021-003063-10-IT   Australia;Bulgaria;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States
Dapsone
   All India Institute of Medical Sciences, Bhubaneswar
      2023   Phase 4   NCT05984381   India
Data report
   Assistance Publique Hopitaux De Marseille
      2018   -   NCT03636763   France
Dermoval
   CHU de Limoges
      2007   -   EUCTR2007-003545-32-FR   France
   University Hospital, Rouen
      2001   -   NCT00213421   France
Dexamethasone 0.5MG/5ML solution
   University of California, San Francisco
      2020   Phase 2   NCT04540133   United States
DF2156A
   DOMPE' s.p.a.
      2011   -   EUCTR2011-000756-42-IT   Germany;Italy
   Dompé Farmaceutici S.p.A
      2012   Phase 2   NCT01571895   Germany;Italy
   Dompé s.p.a.
      -   -   EUCTR2011-000756-42-DE   Germany;Italy
Double dose
   Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
      2022   Phase 1/Phase 2   NCT05520086   Spain
Doxycycline
   CHU de Reims
      2013   -   NCT02837965   France
   University of Nottingham
      2009   Phase 4   EUCTR2007-006658-24-GB   Germany;United Kingdom
   Universitätsklinikum Schleswig-Holstein
      2009   Phase 4   EUCTR2007-006658-24-DE   Germany;United Kingdom
Dupilumab
   Peking University First Hospital
      2022   -   NCT05649579   China
   Peking university first hospital
      2024   -   ChiCTR2400085072   China
   Regeneron Pharmaceuticals
      2023   -   NCT05906706   -
      2020   Phase 2/Phase 3   NCT04206553   Australia;France;Germany;Israel;Japan;Poland;Spain;Taiwan;United States
   Regeneron Pharmaceuticals, Inc.
      2022   Phase 2;Phase 3   EUCTR2019-003520-20-PL   Australia;France;Germany;Israel;Japan;Poland;Spain;Taiwan;United States
      2020   Phase 2-3   JPRN-jRCT2080225313   Europe;Japan;North America
      2020   Phase 2;Phase 3   EUCTR2019-003520-20-FR   Australia;France;Germany;Japan;Poland;Spain;United States
      2020   Phase 2;Phase 3   EUCTR2019-003520-20-DE   Australia;France;Germany;Israel;Japan;Poland;Spain;Taiwan;United States
   Xijing Hospital
      2022   Phase 0   ChiCTR2200058412   China
Dupixent
   Regeneron Pharmaceuticals, Inc.
      2022   Phase 2;Phase 3   EUCTR2019-003520-20-PL   Australia;France;Germany;Israel;Japan;Poland;Spain;Taiwan;United States
      2020   Phase 2;Phase 3   EUCTR2019-003520-20-FR   Australia;France;Germany;Japan;Poland;Spain;United States
      2020   Phase 2;Phase 3   EUCTR2019-003520-20-DE   Australia;France;Germany;Israel;Japan;Poland;Spain;Taiwan;United States
Efgartigimod alfa
   ARGENX BV
      2023   Phase 3   EUCTR2021-003063-10-IT   Australia;Bulgaria;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States
   argenx BV
      2023   Phase 2;Phase 3   EUCTR2021-003087-27-SK   Australia;Bulgaria;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States
      2023   Phase 2;Phase 3   EUCTR2021-003087-27-RO   Australia;Bulgaria;Canada;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2021-003063-10-SK   Australia;Bulgaria;Canada;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Serbia;Slovakia;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2021-003063-10-NL   Australia;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2021-003063-10-HU   Australia;Bulgaria;Canada;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2021-003063-10-HR   Australia;Bulgaria;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States
      2023   Phase 3   EUCTR2021-003063-10-GR   Australia;Bulgaria;Canada;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2021-003063-10-ES   Australia;Bulgaria;China;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States
      2023   Phase 3   EUCTR2021-003063-10-DE   Australia;Bulgaria;Canada;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Serbia;Slovakia;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2021-003063-10-CZ   Australia;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States
      2023   Phase 3   EUCTR2021-003063-10-BG   Australia;Bulgaria;Canada;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-003087-27-NL   Australia;Bulgaria;Canada;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-003087-27-LV   Australia;Bulgaria;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-003087-27-HU   Australia;Bulgaria;Canada;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-003087-27-HR   Australia;Bulgaria;China;Croatia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-003087-27-GR   Australia;Bulgaria;Canada;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-003087-27-FR   Australia;Bulgaria;China;Croatia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-003087-27-ES   Australia;Bulgaria;China;Croatia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-003087-27-DE   Australia;Bulgaria;Canada;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Serbia;Slovakia;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-003087-27-BG   Australia;Bulgaria;Canada;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States
Efgartigimod PH20 SC
   ARGENX BV
      2023   Phase 3   EUCTR2021-003063-10-IT   Australia;Bulgaria;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States
   argenx
      2023   Phase 3   NCT05681481   Australia;Bulgaria;China;Croatia;Czechia;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;Serbia;Slovakia;Spain;United Kingdom;United States
      2022   Phase 2/Phase 3   NCT05267600   Australia;Bulgaria;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Serbia;Slovakia;Spain;United Kingdom;United States
   argenx BV
      2023   Phase 2;Phase 3   EUCTR2021-003087-27-SK   Australia;Bulgaria;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States
      2023   Phase 2;Phase 3   EUCTR2021-003087-27-RO   Australia;Bulgaria;Canada;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2021-003063-10-SK   Australia;Bulgaria;Canada;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Serbia;Slovakia;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2021-003063-10-NL   Australia;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2021-003063-10-HU   Australia;Bulgaria;Canada;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2021-003063-10-HR   Australia;Bulgaria;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States
      2023   Phase 3   EUCTR2021-003063-10-GR   Australia;Bulgaria;Canada;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2021-003063-10-ES   Australia;Bulgaria;China;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States
      2023   Phase 3   EUCTR2021-003063-10-DE   Australia;Bulgaria;Canada;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Serbia;Slovakia;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2021-003063-10-CZ   Australia;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States
      2023   Phase 3   EUCTR2021-003063-10-BG   Australia;Bulgaria;Canada;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-003087-27-NL   Australia;Bulgaria;Canada;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-003087-27-LV   Australia;Bulgaria;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-003087-27-HU   Australia;Bulgaria;Canada;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-003087-27-HR   Australia;Bulgaria;China;Croatia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-003087-27-GR   Australia;Bulgaria;Canada;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-003087-27-FR   Australia;Bulgaria;China;Croatia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-003087-27-ES   Australia;Bulgaria;China;Croatia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-003087-27-DE   Australia;Bulgaria;Canada;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Serbia;Slovakia;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-003087-27-BG   Australia;Bulgaria;Canada;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States
Endoxan
   CHU-Hôpitaux de Rouen
      2017   Phase 3   EUCTR2016-004666-26-FR   France
Fasenra
   AstraZeneca AB
      2021   Phase 3   EUCTR2020-000287-32-GR   Australia;Bulgaria;China;France;Germany;Greece;Israel;Italy;Japan;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000287-32-DE   Australia;Bulgaria;China;France;Germany;Greece;Israel;Italy;Japan;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000287-32-BG   Australia;Bulgaria;China;France;Germany;Greece;Israel;Italy;Japan;Spain;United Kingdom;United States
Galen
   ARGENX BV
      2023   Phase 3   EUCTR2021-003063-10-IT   Australia;Bulgaria;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States
Halometasone
   Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine
      2009   -   ChiCTR-IOR-15007146   China
   The First Affiliated Hospital of Kunming Medical University
      2020   Phase 4   ChiCTR2000029007   China
Imatinib
   Kabashima Kenji
      2018   Phase 0   JPRN-jRCTs051180069   -
Impedance analysis
   University Hospital, Rouen
      2015   Phase 4   NCT02360202   France
Interleukin 2
   The First Affiliated Hospital of Nanchang University
      2023   Phase 4   ChiCTR2500099202   China
Interleukin-2
   Dermatology Hospital, Southern Medical University
      2020   Phase 0   ChiCTR2000028707   China
IPH5401
   CHU NICE
      2020   Phase 2   EUCTR2020-002912-34-FR   France
   Centre Hospitalier Universitaire de Nice
      2020   Phase 2   NCT04563923   France
Ixekizumab
   Mayo Clinic
      2017   Phase 2   NCT03099538   United States
Janus kinase inhibitor
   Chao Ji
      2022   -   NCT06561256   China
Ladarixin
   DOMPE' s.p.a.
      2011   -   EUCTR2011-000756-42-IT   Germany;Italy
   Dompé s.p.a.
      -   -   EUCTR2011-000756-42-DE   Germany;Italy
Large dose OF prednisolone plus intra-lesional OF triamcinolone acetonide followed THE systemic combination OF mycophenolate mofetil (MMF), dapsone and LOW dose prednisolone IN treatment OF MMP
   Tanta University
      2020   Phase 2/Phase 3   NCT04744623   Egypt
Leflunomide
   University Hospital, Limoges
      2007   Phase 2   NCT00802243   France
Liquid bubble sampling
   CHU de Reims
      2022   -   NCT06479018   France
Mabthera
   CHU de Rouen
      2023   Phase 4   EUCTR2022-000060-22-FR   France
   CHU-Hôpitaux de Rouen
      2018   Phase 3   EUCTR2018-001417-32-FR   France
      2017   Phase 3   EUCTR2016-004666-26-FR   France
   University Hospital, Rouen
      2008   Phase 3   NCT00525616   France
MabthéRA
   CHU-Hôpitaux de Rouen
      2009   -   EUCTR2008-005266-31-FR   France
MathéRA
   CHU-Hôpitaux de Rouen
      2009   -   EUCTR2008-005266-31-FR   France
MEDI-563
   ASTRAZENECA AB
      2021   Phase 3   EUCTR2020-000287-32-IT   Australia;Bulgaria;France;Germany;Israel;Italy;Japan;Spain;United States
   AstraZeneca AB
      2021   Phase 3   EUCTR2020-000287-32-GR   Australia;Bulgaria;China;France;Germany;Greece;Israel;Italy;Japan;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000287-32-FR   Australia;Bulgaria;France;Germany;Greece;Israel;Italy;Japan;Spain;United States
      2021   Phase 3   EUCTR2020-000287-32-DE   Australia;Bulgaria;China;France;Germany;Greece;Israel;Italy;Japan;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000287-32-BG   Australia;Bulgaria;China;France;Germany;Greece;Israel;Italy;Japan;Spain;United Kingdom;United States
Mepolizumab
   University Hospital Inselspital, Berne
      2013   Phase 2   NCT01705795   Switzerland
Methotrexate
   All India Institute of Medical Sciences, Bhubaneswar
      2023   Phase 4   NCT05984381   India
   CHU de Reims
      2013   -   NCT02837965   France
   Washington University School of Medicine
      2022   Phase 2   NCT05263505   United States
Methylprednisolone
   The First Affiliated Hospital of Kunming Medical University
      2020   Phase 4   ChiCTR2000029007   China
Minocycline
   Institute of dermatology, Chinese Academy of Medical Sciences
      2011   -   ChiCTR-TRC-12003592   China
   Peking University First Hospital
      2022   Phase 4   ChiCTR2200060454   China
Mitomycin
   Department of Ophthalmology, Keio University School of Medicine
      2013   -   JPRN-UMIN000002948   Japan
Mometasone furoate
   Alkahest, Inc.
      2020   Phase 2   NCT04499235   Germany
MTX
   Institute of dermatology, Chinese Academy of Medical Sciences
      2011   -   ChiCTR-TRC-12003538   China
   Institute of dermatology; Chinese Academy of Medical Sciences
      2011   -   ChiCTR-TRC-12003593   China
Mycophenolate
   Washington University School of Medicine
      2022   Phase 2   NCT05263505   United States
Myfortic 180 MG filmtabletten
   Georg-August-Universität Göttingen, Bereich Humanmedizin
      2005   Phase 2   EUCTR2005-001827-12-DE   Germany
Nicotinamide
   Institute of dermatology, Chinese Academy of Medical Sciences
      2011   -   ChiCTR-TRC-12003592   China
NNC0215-0384
   CHU NICE
      2020   Phase 2   EUCTR2020-002912-34-FR   France
Nomacopan
   AKARI Therapeutics
      2022   Phase 3   NCT05061771   Germany;Netherlands;Poland;United States
   Akari Therapeutics Plc
      2022   Phase 3   EUCTR2020-005987-67-NL   Germany;Netherlands;United States
      2021   Phase 3   EUCTR2020-005987-67-DE   Germany;United States
NPB-01
   Nihon Pharmaceutical Co., Ltd
      2011   Phase 3   NCT01408550   Japan
      2008   Phase 2   NCT00809822   Japan
Omalizumab
   University of Iowa
      2007   Phase 4   NCT00472030   United States
Otezla
   Universitair Medisch Centrum Groningen
      2019   Phase 2   EUCTR2018-002564-10-NL   Netherlands
Ozonated olive OIL
   Cairo University
      2022   Phase 3   NCT05594472   Egypt
Prednisolone
   All India Institute of Medical Sciences, Bhubaneswar
      2023   Phase 4   NCT05984381   India
   University of Nottingham
      2009   Phase 4   EUCTR2007-006658-24-GB   Germany;United Kingdom
   Universitätsklinikum Schleswig-Holstein
      2009   Phase 4   EUCTR2007-006658-24-DE   Germany;United Kingdom
Prednisone
   ARGENX BV
      2023   Phase 3   EUCTR2021-003063-10-IT   Australia;Bulgaria;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States
   CHU de Reims
      2013   -   NCT02837965   France
   CHU-Hôpitaux de Rouen
      2018   Phase 3   EUCTR2018-001417-32-FR   France
      2009   -   EUCTR2008-005266-31-FR   France
   Institute of dermatology, Chinese Academy of Medical Sciences
      2011   -   ChiCTR-TRC-12003538   China
   Institute of dermatology; Chinese Academy of Medical Sciences
      2011   -   ChiCTR-TRC-12003593   China
   The First Affiliated Hospital of Kunming Medical University
      2020   Phase 4   ChiCTR2000029007   China
   University of Iowa
      2007   Phase 4   NCT00472030   United States
   argenx
      2023   Phase 3   NCT05681481   Australia;Bulgaria;China;Croatia;Czechia;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;Serbia;Slovakia;Spain;United Kingdom;United States
      2022   Phase 2/Phase 3   NCT05267600   Australia;Bulgaria;China;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Serbia;Slovakia;Spain;United Kingdom;United States
Prednisone acetate
   Department of Dermatology, the First Affiliated Hospital of Army Medical University
      2024   Phase 0   ChiCTR2400086721   China
QGE031
   Novartis Pharma AG
      2012   -   EUCTR2012-003370-10-AT   Austria;Germany;Taiwan;United States
   Novartis Pharma Services AG
      2013   Phase 2   EUCTR2012-003370-10-FR   Austria;France;Germany;Taiwan;United States
      2013   -   EUCTR2012-003370-10-DE   Austria;Germany;Taiwan;United States
   Novartis Pharmaceuticals
      2013   Phase 2   NCT01688882   Austria;France;Germany;Japan;Taiwan;United States
Radiographs OF THE thoracic and lumbar spine
   Centre Hospitalier Universitaire, Amiens
      2019   Phase 4   NCT03926377   France
RAY121
   Chugai Pharmaceutical
      2024   Phase 1   NCT06723106   Australia;Austria;Bulgaria;Croatia;Czechia;France;Germany;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Romania;Spain;Taiwan;Turkey
      2024   Phase 1   NCT06371417   Australia;Austria;Bulgaria;Canada;Croatia;Czechia;France;Germany;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Romania;Spain;Taiwan;Turkey;United States
Restasis
   UNIVERSITA' CAMPUS BIOMEDICO
      2008   -   EUCTR2008-000480-41-IT   Italy
Riboflavin
   Joseph B. Ciolino, MD
      2012   Phase 1/Phase 2   NCT01582880   United States
Rituximab
   CHU de Rouen
      2023   Phase 4   EUCTR2022-000060-22-FR   France
   CHU-Hôpitaux de Rouen
      2018   Phase 3   EUCTR2018-001417-32-FR   France
      2017   Phase 3   EUCTR2016-004666-26-FR   France
   Department of Dermatology, Keio University School of Medicine
      2014   Phase 1,2   JPRN-UMIN000015451   Japan
   Duke University
      2005   Phase 1/Phase 2   NCT00286325   United States
   Kanaoka Miwa
      2014   -   JPRN-jRCTs031180220   -
   Research group of rare intractable dermatologial disorder
      2010   Phase 2   JPRN-UMIN000004428   Japan
   University of Alabama at Birmingham
      2006   Phase 1/Phase 2   NCT00584935   United States
Rituximab 1G IV
   University Hospital, Rouen
      2019   Phase 3   NCT03295383   France
Rituximab combined with omalizumab
   University of California, Davis
      2017   Phase 3   NCT04128176   United States
RVA576
   AKARI Therapeutics
      2022   Phase 3   NCT05061771   Germany;Netherlands;Poland;United States
      2018   Phase 2   NCT04035733   Germany;Netherlands
   Akari Therapeutics Plc
      2022   Phase 3   EUCTR2020-005987-67-NL   Germany;Netherlands;United States
      2021   Phase 3   EUCTR2020-005987-67-DE   Germany;United States
   Akari Therapeutics Plc.
      2018   Phase 2   EUCTR2017-002836-18-NL   Germany;Netherlands
      2018   Phase 2   EUCTR2017-002836-18-DE   Germany;Netherlands
Silver
   Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.
      2015   -   NCT02365675   Mexico
Simvastatin-ratiopharm
   Philipps-Universität Marburg
      2013   -   EUCTR2011-004361-32-DE   Germany
Single dose
   Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
      2022   Phase 1/Phase 2   NCT05520086   Spain
SOLU-medrone
   Moorfields Eye Hospital NHS Foundation Trust
      2005   Phase 4   EUCTR2005-002391-14-GB   United Kingdom
Tildrakizumab prefilled syringe
   Brigham and Women's Hospital
      2020   Early Phase 1   NCT04465292   -
Tofacitinib
   Department of Dermatology, the First Affiliated Hospital of Army Medical University
      2024   Phase 0   ChiCTR2400086721   China
Topical garamycin cream
   Cairo University
      2022   Phase 3   NCT05594472   Egypt
Topical infliximab
   James Chodosh, MD, MPH
      2014   Phase 1/Phase 2   NCT02126020   Canada;United States
Treatment with topical superpotent corticosteroid therapy
   CHU de Reims
      2013   -   NCT02837965   France
Tripterygium
   Institute of dermatology, Chinese Academy of Medical Sciences
      2011   -   ChiCTR-TRC-12003592   China
Ustekinumab
   CHU de Reims
      2020   Phase 2   NCT04117932   France